Poseida Therapeutics
Poseida Therapeutics is working on cell therapies, using gene engineering platform technologies. The firm has the goal of bringing new treatments to patients with serious diseases, first in the blood-based cancer multiple myeloma and eventually in solid tumors like prostate cancer.
"Poseida is developing two approaches with next-generation CAR-T therapies: autologous and allogeneic. Autologous therapies are fully customized treatments created using an individual patient’s own T cells. In contrast, allogeneic therapies, use T cells derived from healthy donors, allowing the firm to make an off-the-shelf treatment for hundreds or thousands of patients from a single manufacturing run."
Latest Poseida Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze